Evidence map›Paper›PMID 39623260›Full record

Trial reportNan fang yi ke da xue xue bao = Journal of Southern Medical University2024

[Megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early-stage endometrial adenocarcinoma: a prospective study].

Yuanyuan Wang, Tianjiao Lai, Danxia Chu, Jing Bai, Shuping Yan, Haixia Qin, Ruixia Guo

Abstract readRandomized Controlled TrialEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yuanyuan WangDepartment of Gynecology, First Affiliated Hospital of Xinxiang Medical University, Weihui 453100, China.
Tianjiao LaiDepartment of Gynecology, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Danxia ChuDepartment of Gynecology, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Jing BaiDepartment of Gynecology, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Shuping YanDepartment of Gynecology, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Haixia QinDepartment of Gynecology, First Affiliated Hospital of Xinxiang Medical University, Weihui 453100, China.
Ruixia GuoDepartment of Gynecology, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the efficacy of medroxyprogesterone acetate (MA) plus metformin as the primary fertility-sparing treatment for atypical endometrial hyperplasia (AEH) and early-stage grade 1 endometrial adenocarcinoma (G1 EAC) and the recurrence rate after treatment.

methodsSixty patients (aged 20-42 years) with AEH and/or grade 1 EAC limited to the endometrium were enrolled prospectively and randomized into two groups (

resultsA total of 58 patients completed the treatment. After 9 months of treatment, 23 (76.7%) patients in the combined treatment group and 20 (71.4%) in the control group achieved CR; two patients in the control group achieved CR after converting to the combined treatment. The recurrence rate did not differ significantly between the control group and combined treatment group (30.0%

conclusionMetformin combined with MA may provide an effective option for fertility-sparing treatment of AEH and grade 1 stage IA EAC, and the clinical benefits of metformin for controlling MA-induced weight gain and promoting endometrial expressions of IGFBP-rP1 and p-AMPK while inhibiting p-Akt expression warrants further study.

Indexed as

Endometrial HyperplasiaEndometrial NeoplasmsMegestrol AcetateMetforminAdenocarcinomaAdultFemaleFertility PreservationHumansInsulin-Like Growth Factor Binding Protein 1Medroxyprogesterone AcetateProspective StudiesTreatment OutcomeYoung AdultInsulin-Like Growth Factor Binding Protein 1Medroxyprogesterone AcetateMegestrol AcetateMetforminatypical endometrial hyperplasiaendormetrial adenocarcinomafertility-sparing treatmentinsulin-like growth factor binding protein-related protein 1megestrol acetatemetformin

Identifiers

PMID39623260
PMCPMC11605202

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.